{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:22:44Z","timestamp":1790238164407,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19gk0110037"],"award-info":[{"award-number":["JP19gk0110037"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Congenital cytomegalovirus (CMV) disease, a common mother-to-child infection, can lead to neurological sequelae. Some clinical trials have shown that oral valganciclovir (VGCV) can improve hearing and neurodevelopmental impairment in infants with congenital CMV disease. However, VGCV has neither been approved in Japan nor other countries as a treatment for this disease by the government health insurance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study is a non-randomized, prospective, open-label, multicenter, single-arm clinical trial and will include subjects meeting the following criteria: confirmation of positive CMV-DNA amplification in urine by an in vitro diagnostic test within 21 days of age; congenital CMV disease with one or more central nervous system disorders\u2014microcephaly, hydrocephalus or ventricular enlargement, periventricular calcification, cortical hypoplasia or white matter injury, retinal choroiditis, and abnormal auditory brainstem response (ABR); and infants within 2 months of age with a gestational age \u226532 weeks at birth and weighing \u22651800\u200ag at the time of registration. Subjects will be orally administered 16\u200amg\/kg VGCV twice daily for 6 months. The target number of cases for enrollment between February 3, 2020 and July 31, 2021 is 25. Primary endpoint is the change in whole blood CMV loads before and after 6 months of treatment. The important secondary endpoint is the change in ABR (both best and total ear hearing assessments) before and after 6 months of treatment. The safety endpoints are adverse events and drug side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>To the best of our knowledge, this multicenter, open-label, single-arm study will be the first well-designed clinical trial to evaluate the efficacy of oral VGCV in infants with congenital CMV diseases. The findings will reveal the efficacy and safety of oral VGCV treatments and enable the approval of oral VGCV as a treatment for infants with congenital CMV disease by the government health insurance of Japan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019765","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T05:53:43Z","timestamp":1587794023000},"page":"e19765","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease"],"prefix":"10.1097","volume":"99","author":[{"given":"Ichiro","family":"Morioka","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Child Health, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Kakei","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Omori","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Social\/Community Medicine and Health Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumichi","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Fujita Health University School of Medicine, Toyoake"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Moriuchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nagasaki University Graduate School of Medicine, Nagasaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ANC.0000000000000242","article-title":"Congenital cytomegalovirus","volume":"16","author":"Mestas","year":"2016","journal-title":"Adv Neonatal Care"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"e000118","DOI":"10.1136\/bmjopen-2011-000118","article-title":"Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study","volume":"1","author":"Koyano","year":"2011","journal-title":"BMJ Open"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ped.13433","article-title":"Congenital cytomegalovirus in Japan: more than 2 year follow up of infected newborns","volume":"60","author":"Koyano","year":"2018","journal-title":"Pediatr Int"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678707.2020.1709441","article-title":"Congenital cytomegalovirus infection: epidemiology, prediction, diagnosis, and emerging treatment options for symptomatic infants","volume":"8","author":"Nagano","year":"2020","journal-title":"Expert Opin Orphan Drugs"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"issue":"(suppl)","key":"R7-20230915","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jcv.2009.08.012","article-title":"Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system","volume":"46","author":"Oliver","year":"2009","journal-title":"J Clin Virol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.braindev.2015.08.003","article-title":"Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment","volume":"38","author":"Nishida","year":"2016","journal-title":"Brain Dev"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"E1388","DOI":"10.3390\/ijms20061388","article-title":"Efficacy of valganciclovir treatment depends on the severity of hearing dysfunction in symptomatic infants with congenital cytomegalovirus infection","volume":"20","author":"Ohyama","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.braindev.2019.04.016","article-title":"Prediction of poor neurological development in patients with symptomatic congenital cytomegalovirus diseases after oral valganciclovir treatment","volume":"41","author":"Fukushima","year":"2019","journal-title":"Brain Dev"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcv.2015.01.015","article-title":"Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening","volume":"65","author":"Kawada","year":"2015","journal-title":"J Clin Virol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:12:17Z","timestamp":1694823137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019765"}},"subtitle":["Study Protocol Clinical Trial (SPIRIT Compliant)"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":13,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019765","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}